ATE264343T1 - Unmodifizierte hämoglobine und deren verwendung - Google Patents

Unmodifizierte hämoglobine und deren verwendung

Info

Publication number
ATE264343T1
ATE264343T1 AT98906222T AT98906222T ATE264343T1 AT E264343 T1 ATE264343 T1 AT E264343T1 AT 98906222 T AT98906222 T AT 98906222T AT 98906222 T AT98906222 T AT 98906222T AT E264343 T1 ATE264343 T1 AT E264343T1
Authority
AT
Austria
Prior art keywords
sno
groups
methods
nitrosated
tissues
Prior art date
Application number
AT98906222T
Other languages
English (en)
Inventor
Jonathan S Stamler
Andrew J Gow
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/796,164 external-priority patent/US6884773B1/en
Priority claimed from US08/874,992 external-priority patent/US6911427B1/en
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of ATE264343T1 publication Critical patent/ATE264343T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT98906222T 1997-02-06 1998-02-05 Unmodifizierte hämoglobine und deren verwendung ATE264343T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/796,164 US6884773B1 (en) 1995-09-15 1997-02-06 Modified hemoglobins, including nitrosylhemoglobins, and uses thereof
US08/874,992 US6911427B1 (en) 1995-09-15 1997-06-12 No-modified hemoglobins and uses therefore
PCT/US1998/002383 WO1998034955A1 (en) 1997-02-06 1998-02-05 No-modified hemoglobins and uses therefor

Publications (1)

Publication Number Publication Date
ATE264343T1 true ATE264343T1 (de) 2004-04-15

Family

ID=27121701

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906222T ATE264343T1 (de) 1997-02-06 1998-02-05 Unmodifizierte hämoglobine und deren verwendung

Country Status (7)

Country Link
EP (1) EP1015490B1 (de)
JP (1) JP2002513400A (de)
AT (1) ATE264343T1 (de)
AU (1) AU6150298A (de)
CA (1) CA2278784A1 (de)
DE (1) DE69823211T2 (de)
WO (1) WO1998034955A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6916471B2 (en) 1995-09-15 2005-07-12 Duke University Red blood cells loaded with S-nitrosothiol and uses therefor
US6087087A (en) * 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
JP2000230000A (ja) 1999-02-08 2000-08-22 Hokkaido Univ 一酸化窒素代謝物−ポリオキシアルキレン−ヘモグロビン結合体
CA2266174A1 (en) 1999-03-18 2000-09-18 Hemosol Inc. Hemoglobin-antioxidant conjugates
EP1204870B1 (de) * 1999-08-02 2010-01-20 Duke University Methode zur bestimmung der physiologischen wirkungen von hämoglobin
US6314956B1 (en) * 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders
US6627602B2 (en) * 2001-11-13 2003-09-30 Duke University Preventing desensitization of receptors
CA2487719A1 (en) * 2002-05-29 2003-12-11 Duke University Measuring nitric oxide in blood gases and treatments based thereon
WO2004054433A2 (en) * 2002-12-12 2004-07-01 Duke University Forming iron nitrosyl hemoglobin
DE102004043279A1 (de) * 2004-09-08 2006-03-23 Theo Woike Verfahren und Vorrichtung zum biologischen, medizinischen und pharmazeutischen Gebrauch des Nitrosylmoleküls NO durch optische Anregung von metastabilen Zuständen in Nitrosylkomplexen
US8735354B2 (en) * 2008-11-07 2014-05-27 Uab Research Foundation Endothelium mimicking nanomatrix
US7989593B1 (en) * 2010-05-27 2011-08-02 Bing Lou Wong Method for the preparation of a high-temperature stable oxygen-carrier-containing pharmaceutical composition and the use thereof
EP2776047A4 (de) * 2011-11-07 2015-07-22 Gen Hospital Corp Behandlung von erythrozyten
EP3444615B1 (de) * 2017-08-15 2021-09-08 Freiberg Instruments GmbH Verfahren und zusammensetzungen zur diagnostischen beurteilung und therapeutischen korrektur des no-haem-signalwegs bei tieren und menschen
CN111912802B (zh) * 2020-08-25 2023-05-26 潍坊市生态环境局寿光分局 一种分光光度法检测亚硝酸盐氮的方法
WO2023018861A1 (en) * 2021-08-13 2023-02-16 University Hospitals Cleveland Medical Center Non-invasive measurement of endogenous s-nitrosothiols

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1023905T3 (da) * 1991-11-14 2005-05-30 Brigham & Womens Hospital Farmaceutisk præparat indeholdende S-nitroso-immunoglobuliner og anvendelse deraf
TW381022B (en) * 1993-08-16 2000-02-01 Hsia Jen Chang Compositions and methods utilizing nitroxides to avoid oxygen toxicity, particularly in stabilized, polymerized, conjugated, or encapsulated hemoglobin used as a red cell substitute
AU5368296A (en) * 1995-03-24 1996-10-16 Brigham And Women's Hospital Nitrosylated blood substitutes
US6197745B1 (en) * 1995-09-15 2001-03-06 Duke University Methods for producing nitrosated hemoglobins and therapeutic uses therefor

Also Published As

Publication number Publication date
DE69823211T2 (de) 2004-08-26
EP1015490A1 (de) 2000-07-05
EP1015490B1 (de) 2004-04-14
AU6150298A (en) 1998-08-26
WO1998034955A1 (en) 1998-08-13
CA2278784A1 (en) 1998-08-13
DE69823211D1 (de) 2004-05-19
JP2002513400A (ja) 2002-05-08

Similar Documents

Publication Publication Date Title
ATE264343T1 (de) Unmodifizierte hämoglobine und deren verwendung
Grisham et al. I. Physiological chemistry of nitric oxide and its metabolites: implications in inflammation
Reeder et al. Toxicity of myoglobin and haemoglobin: oxidative stress in patients with rhabdomyolysis and subarachnoid haemorrhage
CY1111371T1 (el) Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο
HUP0500643A2 (hu) Eljárások endogén eritropoetin szintjének növelésére
HUP9800028A2 (hu) Több tumor esetében rendellenes sejtszaporodás előidézésében közrejátszó gének
ES2115096T3 (es) Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
BG66080B1 (bg) Заместени тиоацетамиди
DE59303365D1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
PT934309E (pt) Novas piridil-alcano-amidas como agentes citostaticos e imunossupressivos
HUP0303463A1 (hu) Dimer izoflavonok
DK0689586T3 (da) VPR-funktion og -aktivitet
BE1002375A3 (fr) Matieres biologiques, procede pour la production de matieres biologiques et pour l'utilisation de telles matieres en therapie.
Koprowski et al. The role of nitric oxide in physiology and pathophysiology
Ishima et al. One-step preparation of S-nitrosated human serum albumin with high biological activities
DE69112885T2 (de) Zwischenprodukte für Difluoroglutamsäurekonjugate mit Folaten und Antifolaten zur Behandlung von neoplastischen Krankheiten.
Barnard et al. Protective role of hemopexin on heme-dependent lung oxidative stress
Witt et al. Tributyrin plus all‐trans‐retinoic acid efficiently induces fetal hemoglobin expression in human erythroleukemia cells
Berthold et al. Chemical Modifications of tyrosyl Residue (s) and Action of Human‐Fibroblast Interferon
Suardi et al. In Vitro Effects of Low Level Laser Irradiation on Blood Protein
Ischiropoulos et al. A comparison of the biological reactivity of nitric oxide and peroxynitrite
Pyror The role of free radicals in smog-induced pathology and protection by vitamin E
Sagai Experimental study on tumor promoting effects of nitrogen dioxide (NO2) and ozone (O3)
DE50014417D1 (de) Nukleinsäure, die für ein protein der ctage-familie kodiert, deren verwendung und herstellung
Jasinski Impact of Gaseous Nitric Oxide and Carbon Monoxide on Normal Excisional, Diabetic Excisional and Burn Wound Healing

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties